Koon Yan Pak, Ph.D.

Co-Founder and Chief Executive Officer

Dr. Pak has been in the Biotechnology field for over two decades. He was formerly associated with Centocor, a top-tier biopharmaceutical company. Dr. Pak is the former President of the Chinese American Society of Nuclear Medicine and the former Vice Chair of the Global Monte Jade Science and Technology Association, and the co-founder and the former Chairman of the Chinese Entrepreneur Association. Currently, he is a board member of Ben Franklin Minority Technology Advisory board and of the Advisory Council to the Pennsylvania Academy of Sciences. Dr. Pak is also an advisor to the National University of Singapore-Bio Valley Program. Dr. Pak holds ten patents in the diagnostic imaging and therapy field and has published more than fifty articles covering the use of antibodies for cancer and for cardiovascular imaging diagnostics. Dr. Pak’s recent awards include SUNY Honor Roll of Alumni, Ben Franklin Emerging Business Award and Outstanding Asian American Business Award.

Jeffrey A. Mattis, Ph.D.

Senior Vice President of Scientific Affairs

Dr. Mattis is a biopharmaceutical executive with more than 30 years experience in the technical development of biopharmaceuticals. Dr. Mattis previously served as Vice President of Pharmaceutical Development for Centocor. Dr. Mattis was instrumental in the technical development of several biopharmaceuticals approved for the US and multinational markets. These include ReoPro®, an anti-platelet drug for use in coronary angioplasty; Remicade®, a drug for treatment of Crohn’s disease and rheumatoid arthritis; and Myoscint®, a cardiac imaging agent.

Brian D. Gray, Ph.D.

Vice President of Research

Dr. Gray earned a Ph.D. in Organic Chemistry in 1983 from the University of Dundee, Scotland, and carried out post-doctoral research involving the synthesis of complex organic molecules first initially at Oregon State University and then at SmithKline Beckman. In 1988 he helped co-found Zynaxis, Inc., a biotechnology company, with colleagues from SmithKline, and rose to the position of Director of Medicinal Chemistry. From 1997 until May 2007 he served as V.P. of Chemical Research for PTI Research, Inc. (PTIR), a firm that provides contract and custom chemistry services for life science and pharmaceutical researchers in academia and industry, specializing in the synthesis of heterocyclic organics, bioconjugates, and compounds requiring complex multistep syntheses. He was also the PI on several NIH grants while at PTIR and was responsible for the design and development of novel research reagents for neuronal tract tracing (NeuroVue™ dyes) and cell tracking (CellVue™ dyes) now being manufactured and sold by MTTI. Dr Gray has more than 22 years experience in the design and synthesis of novel compounds for biomedical research, diagnostics and drug delivery applications, with special expertise in the chemistry of fluorescent dyes and lipophilic agents.